Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse
Archives of Medical Science · 21.08.2026
DOI: 10.5114/aoms/230992 ↗Kurz gefasst
Leserbrief in der Zeitschrift Archives of Medical Science, online erschienen am 21.08.2026. Verfasst von Huan Xie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Army Medical Center of PLA, Chongqing, China. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Extramedullary disease (EMD) is an aggressive form of multiple myeloma (MM). The reported incidence ranges from 0.5% to 4.8% among patients with newly diagnosed MM
Autor:innen und Institutionen
- Department of Hematology, Army Medical Center of PLA, Chongqing, China.
Zitieren
APA
Xie, H., Luo, R., & Zeng, D. (2026). Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse. Archives of Medical Science. https://doi.org/10.5114/aoms/230992
Vancouver
Xie H, Luo R, Zeng D. Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse. Archives of Medical Science. 2026. doi:10.5114/aoms/230992
BibTeX
@article{Xie2026,
author = {Xie, Huan and Luo, Ran and Zeng, Dongfeng},
title = {Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse},
journal = {Archives of Medical Science},
year = {2026},
doi = {10.5114/aoms/230992}
}
EUVIMED